Formulations (oral and topical cream) containing anti-cancer agents to prevent or treat melanoma

Technology #d-1052

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Sanjay Srivastava
Dr. Sanjay K. Srivastava is a Professor of Biomedical Sciences specializing in Cancer Biology, Chemoprevention and Therapeutics.
External Link (www.ttuhsc.edu)
Patent Protection

Provisional Patent Application Filed

Researcher has developed a new drug delivery system for oral and topical administration of a promising anti-cancer agent for the treatment of melanoma.  A self-emulsifying nanoemulsion system was developed for oral delivery that resulted in entrapment efficiency of 90% with 90% of the drug released within two hours in simulated gastric fluid.  The formulation had similar efficacy inhibiting melanoma cell growth as the compound solubilized in DMSO with no side effects in mice.  The compound can also be applied topically as a trasnsdermal, nano-emulsion cream as a preventative treatment or as a post-surgical treatment to prevent relapse of melanoma. 

Reference Number: D-1052 

Market Applications:

  • Cancer therapeutics
  • Natural supplements 

Features, Benefits & Advantages:

  • Drug delivery system for PL
  • Non-toxic 
  • Stable
  • High entrapment efficiency and subsequent release
  • In-vivo delivery
  • Topical or oral application 

Intellectual Property:

  • A U.S. Provisional Patent, Serial 62/189,377 was filed on 07/07/2015.

Development Stage:

  • This invention has been reduced to practice in vitro, ex vivo and in vivo.  

Keywords: piplartine, melanoma, oral, topical